BraTS-PEDs: Results of the Multi-Consortium International Pediatric Brain Tumor Segmentation Challenge 2023

Anahita **Fathi Kazerooni** 1, Nastaran **Khalili** 1, Xinyang Liu 2, Debanjan **Haldar** 3, Zhifan **Jiang** 2, Anna **Zapaishchykova** 4, Julija **Pavaine** ⁵ , Lubdha M. **Shah** ⁶ , Blaise V. **Jones** ⁷ , Nakul **Sheth** ⁸ , Sanjay P. **Prabhu** ⁹ , Aaron S. **McAllister** ¹⁰ , Wenxin **Tu** ¹¹ , Khanak K. **Nandolia** ¹² , Andres F. **Rodriguez** ¹³ , Ibraheem Salman **Shaikh** ¹⁴ , Mariana **Sanchez-**Montano ¹⁵, Hollie Anne Lai ¹⁶, Maruf Adewole ¹⁷, Jake Albrecht ¹⁸, Udunna Anazodo ¹⁹, Hannah Anderson ²⁰, Syed Muhammed **Anwar** ², Alejandro **Aristizabal** ²¹, Sina **Bagheri** 20, Ujjwal **Baid** 22, Timothy **Bergquist** 18, Austin J. **Borja** 23, Evan **Calabrese** ²⁴ , Verena **Chung** ¹⁸ , Gian-Marco **Conte** ²⁵ , James **Eddy** ¹⁸ , Ivan **Ezhov** ²⁶ , Ariana M. **Familiar** ¹ , Keyvan Farahani ²⁷, Deep Gandhi ¹, Anurag Gottipati ¹, Shuvanjan Haldar ²⁸, Juan Eugenio Iglesias ²⁹, Anastasia Janas ³⁰, Elaine Elaine ³¹, Alexandros Karargyris ²¹, Hasan Kassem ²¹, Neda Khalili ¹, Florian Kofler ³², Dominic LaBella ³³, Koen Van Leemput 34, Hongwei B. Li 35, Nazanin Maleki 30, Zeke Meier 36, Bjoern Menze 37, Ahmed W. Moawad 38, Sarthak **Pati** ²¹ , Marie **Piraud** ³² , Tina **Poussaint** ⁴ , Zachary J. **Reitman** ³³ , Jeffrey D. **Rudie** ³⁹ , Rachit **Saluja** ⁴⁰ , MIcah **Sheller** ²¹ , Russell Takeshi **Shinohara** ⁴¹ , Karthik **Viswanathan** ¹ , Chunhao **Wang** ³³ , Benedikt **Wiestler** ⁴² , Walter F. Wiggins⁴³, Christos Davatzikos ⁴⁴, Phillip B. Storm ¹, Miriam Bornhorst ⁴⁵, Roger Packer ⁴⁵, Trent Hummel ⁴⁶, Peter **de Blank** 46, Lindsey **Hoffman** 47, Mariam **Aboian** 8, Ali **Nabavizadeh** 1, Jeffrey B. **Ware** 1, Benjamin H. **Kann** 4, Brian **Rood** ⁴⁸ , Adam **Resnick** ¹ , Spyridon **Bakas** ²² , Arastoo **Vossough** ⁸ , Marius George **Linguraru** ²

1 Center for Data-Driven Discovery in Biomedicine (D3b), The Children's Hospital of Philadelphia, PA, USA, **2** Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Hospital, Washington DC, USA, **3** Department of Neurosurgery, Thomas Jefferson University Hospital, PA, USA, **4** Dana-Farber Brigham Cancer Center & Boston Children's Hospital, Boston, MA, USA, **5** Department of Paediatric Radiology, Royal Manchester Children's Hospital, Manchester University Hospitals NHS Foundation Trust, University of Manchester, Manchester, UK, **6** University of Utah, UT, USA, **7** Cincinnati Children's Hospital Medical Center, OH, USA, **8** Department of Radiology, The Children's Hospital of Philadelphia, PA, USA, **9** Division of Neuroradiology, Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, **10** Department of Radiology, Nationwide Children's Hospital, OH, USA, **11** College of Arts and Sciences, University of Pennsylvania, PA, USA, **12** Department of Diagnostic and Interventional Radiology, All India Institute of Medical Sciences, Rishikesh, India, **13** Department of Diagnostic & Interventional Imaging, Neuroradiology section, The University of Texas Health at Houston, Texas, USA, **14** Beth Israel Deaconess Medical Center, Harvard Medical School, MA, USA, **15** UNIDAD DE PATOLOGIA CLINICA:Guadalajara, JALISCO, Mexico, **16** Department of Radiology, Children's Health Orange County, CA, USA, **17** Medical Artificial Intelligence (MAI) Lab, Crestview Radiology, Lagos, Nigeria, **18** Sage Bionetworks, USA, **19** Montreal Neurological Institute (MNI), McGill University, Montreal, QC, Canada, **20** Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, **21** MLCommons, USA, **22** Division of Computational Pathology, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA, **23** Department of Neurosurgery at the University of Southern California, CA, USA, **24** Department of Radiology, Duke University Medical Center, Durham, NC, USA, **25** Mayo Clinic, MN, USA, **26** Department of Informatics, Technical University Munich, Germany, **27** National Cancer Institute, National Institutes of Health, Bethesda, MD, USA, **28** Biomedical Engineering Rutgers University, New Brunswick, NJ, USA, **29** Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, **30** Yale University, New Haven, CT, USA, **31** PrecisionFDA, U.S. Food and Drug Administration, Silver Spring, MD, USA, **32** Helmholtz AI, Helmholtz Munich, Germany, **33** Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA, **34** Department of Applied Mathematics and Computer Science, Technical University of Denmark, Denmark, **35** Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA, USA, **36** Booz Allen Hamilton, McLean, VA, USA, **37** Biomedical Image Analysis & Machine Learning, Department of Quantitative Biomedicine, University of Zurich, Switzerland, **38** Mercy Catholic Medical Center, Darby, PA, USA, **39** University of San Diego, CA, USA, **40** Cornell University, Ithaca, NY, USA, **41** Statistics in Imaging and Visualization Center, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA, **42** Department of Neuroradiology, Technical University of Munich, Munich, Germany, **43** Greensboro Radiology, Greensboro, NC, USA, **44** Center for AI and Data Science for Integrated Diagnostics (AI2D) & Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Philadelphia, PA, USA, **45** Brain Tumor Institute, Children's National Hospital, Washington, arXiv:2407.08855v2 [eess.IV] 16 Jul 2024

DC, USA, **46** Brain Tumor Center, Cincinnati Children's Hospital, Cincinnati, OH, USA, **47** Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, US, **48** Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC, USA

Abstract

Pediatric central nervous system tumors are the leading cause of cancer-related deaths in children. The five-year survival rate for high-grade glioma in children is less than 20%. The development of new treatments is dependent upon multi-institutional collaborative clinical trials requiring reproducible and accurate centralized response assessment. We present the results of the BraTS-PEDs 2023 challenge, the first Brain Tumor Segmentation (BraTS) challenge focused on pediatric brain tumors. This challenge utilized data acquired from multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. BraTS-PEDs 2023 aimed to evaluate volumetric segmentation algorithms for pediatric brain gliomas from magnetic resonance imaging using standardized quantitative performance evaluation metrics employed across the BraTS 2023 challenges. The top-performing AI approaches for pediatric tumor analysis included ensembles of nnU-Net and Swin UNETR, Auto3DSeg, or nnU-Net with a self-supervised framework. The BraTS-PEDs 2023 challenge fostered collaboration between clinicians (neuro-oncologists, neuroradiologists) and AI/imaging scientists, promoting faster data sharing and the development of automated volumetric analysis techniques. These advancements could significantly benefit clinical trials and improve the care of children with brain tumors.

Keywords

Brain Tumor Segmentation, Pediatric Brain Tumors, BraTS-PEDs, Benchmarking

Article informations

©2024 Fathi Kazerooni, et al.. License: [CC-BY 4.0](https://creativecommons.org/licenses/by/4.0/)

1. Introduction

Although rare, pediatric tumors of the central nervous system are the leading cause of cancer-related death in children. While pediatric brain tumors may share certain similarities with adult brain tumors, their imaging and clinical presentations differ significantly. For example, both adult glioblastoma (GBM) and pediatric diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG), are high-grade glial tumors with short average overall survival [\(Mackay et al., 2017;](#page-12-0) [Jansen et al., 2015\)](#page-12-1). The incidence of adult GBM is 3 in 100,000 people, while DMG is approximately three times rarer.

GBMs are most commonly found in the frontal and/or temporal lobes and diagnosed at an average age of 64 years [\(Thakkar et al., 2014\)](#page-13-0). In contrast, DMG is primarily located in the pons and is most often diagnosed in children between 5 and 10 years of age. Enhancing tumor regions on post-gadolinium T1-weighted magnetic resonance imaging (MRI) and radiologically defined necrotic tissue regions are common imaging findings in GBM but are less common or clear in DMG, particularly at initial diagnosis. Therefore, pediatric brain tumors require dedicated imaging tools to aid in their characterization and improve diagnosis and prognosis [\(Familiar et al., 2024\)](#page-12-2).

Pediatric brain tumors vary in aggressiveness and prognosis, presenting with heterogeneous histologic subregions such as peritumoral edematous/infiltrated tissue, necrotic core, and enhancing tumor margin, which are reflected in their radio-phenotypes on multi-parametric MRI (mpMRI) scans [\(Fathi Kazerooni et al., 2023a\)](#page-12-3). Some pediatric brain tumors, such as DIPG, are located in surgically inaccessible areas, making them unresectable. Consequently, tumor progression assessment primarily relies on changes in tumor size measured from longitudinal MRI scans.

The current standard, recommended by the Response Assessment in Pediatric Neuro-Oncology (RAPNO) cooperative working group [\(Erker et al., 2020;](#page-12-4) [Cooney et al.,](#page-12-5) [2020\)](#page-12-5), is based on two-dimensional (2D) linear measurements of the tumor subregions, including enhancing tumor, non-enhancing tumor, cystic components, and peritumoral edematous tissue [\(Familiar et al., 2024\)](#page-12-2), in the axial slice of the largest tumor extent. However, manual measurement has high inter-operator variability and 2D measurements are inaccurate surrogates for tumor volumes as they do not account for the irregularity of tumor shape and appearance. Studies in adult brain tumors have demonstrated the superiority of three-dimensional (3D) volumetric measurement of tumor extent in predicting clinical endpoints over 2D methods [\(Elingson et al., 2022\)](#page-12-6).

Tumor segmentation for volumetric analysis is crucial not only for surgical and treatment planning but also for assessing treatment response and longitudinal monitoring.

The importance of volumetric tumor measurements, and thus automated tumor segmentation, has been increasingly recognized in pediatric brain tumor assessment [\(Jansen](#page-12-1) [et al., 2015;](#page-12-1) [Lazow et al., 2022\)](#page-12-7). However, there is a lack of available automated tools to facilitate the segmentation of tumor subregions on mpMRI scans. A few notable automated tumor segmentation methods have been proposed explicitly for pediatric brain tumors [\(Fathi Kazerooni et al.,](#page-12-3) [2023a;](#page-12-3) [Artzi et al., 2020;](#page-12-8) [Kharaji et al., 2024;](#page-12-9) [Liu et al.,](#page-12-10) [2023;](#page-12-10) [Mansoor et al., 2016;](#page-12-11) [Tor-Diez et al., 2020;](#page-13-1) [Peng](#page-13-2) [et al., 2022;](#page-13-2) [Nalepa et al., 2022;](#page-12-12) [Vossough et al., 2022\)](#page-13-3). Most of these methods focus on the segmentation of the entirety of abnormal signal on T2 fluid attenuated inversion recovery (FLAIR) images [\(Artzi et al., 2020;](#page-12-8) [Nalepa](#page-12-12) [et al., 2022\)](#page-12-12), referred to as the whole tumor (WT) in BraTS terminology [\(Bakas et al., 2018\)](#page-12-13). However, due to the absence of benchmarking platforms, these proposed methods have not been evaluated and compared using the same validation data or through a controlled study design.

The BraTS challenges, organized in conjunction with the Medical Image Computing and Computer Assisted Intervention (MICCAI, https://miccai.org) conferences since 2012, have established a community benchmark dataset and environment for adult brain glioma [\(Bakas et al., 2018;](#page-12-13) [Menze et al., 2014;](#page-12-14) [Bakas et al., 2017;](#page-12-15) [Baid et al., 2021\)](#page-12-16). In 2023, the BraTS challenge expanded to include a variety of tumor entities such as adult glioma, intracranial meningioma [\(LaBella et al., 2023\)](#page-12-17), brain metastases [\(Moawad](#page-12-18) [et al., 2023\)](#page-12-18), Sub-Saharan African glioma, and pediatric tumors [\(Kazerooni et al., 2023b\)](#page-12-19) for the segmentation task. Additionally, new tasks were introduced, including Synthesis (Global) - Missing MRI [\(Li et al., 2023\)](#page-12-20), Synthesis (Local) – Inpainting [\(Kofler et al., 2023\)](#page-12-21), and Augmentation. The formation of the pediatric challenge (BraTS-PEDs) followed the initiative at BraTS 2022, where a small set of 60 pediatric DMGs were included only in the test phase of the challenge. The findings from this evaluation encouraged the organization of a larger and more diverse initiative in 2023, incorporating multi-consortia pediatric data for training, validation, and testing of algorithms.

This manuscript presents the data, design, and outcomes of the BraTS-PEDs 2023 challenge, the first benchmarking initiative focused on pediatric brain tumor segmentation. Through a comprehensive analysis of the performance of participating algorithms, this manuscript aims to establish a standard framework for evaluating pediatric brain tumor segmentation algorithms. The goal is to facilitate clinical translation and extend the application of these algorithms to response assessment in pediatric brain tumors.

2. Data and Methods

2.1 Cohort Description

The BraTS-PEDs 2023 dataset was supported by multiple consortia, including Children's Brain Tumor Network (CBTN, https://cbtn.org/) [\(Lilly et al., 2023\)](#page-12-22), International DIPG/DMG Registry (https://www.dipgregistry.org) and COllaborative Network for NEuro-oncology Clinical Trials (CONNECT, https://connectconsortium.org/), along with additional clinical centers, including Boston's Children Hospital and Yale University. All cases contained pre- and post-gadolinium T1-weighted (labeled as T1 and T1CE, respectively), T2-weighted (T2), and T2-weighted fluid attenuated inversion recovery (T2-FLAIR) images. These conventional mpMRI sequences are commonly acquired as part of standard clinical care for brain tumors. However, the image acquisition protocols, and MRI equipment differ across different institutions, resulting in heterogeneity in image quality and appearance in the multi-consortium cohort. Inclusion criteria comprised of pediatric subjects with: (1) histologically-approved high-grade glioma, i.e., astrocytoma and DMG, including radiologically or histologicallyproven DIPG; (2) availability of all four structural mpMRI sequences on treatment-naive imaging sessions. Exclusion criteria consisted of: (1) images of low quality or with artifacts that would not allow for reliable tumor segmentation; and (2) infants younger than one month of age. In the 2023 BraTS-PEDs, data for 167 patients was included (CBTN, $n = 113$; Boston's Children Hospital, $n = 30$; Yale University, $n = 24$). Data from the International DIPG/DMB Registry was only processed but not segmented for the 2023 challenge, but will be included in the 2024 challenge.

2.2 Imaging Data

For all patients, mpMRI scans were pre-processed using a standardized approach, including conversion of the DI-COM files to the NIfTI file format, co-registration to the same anatomical template (i.e., SRI24) [\(Rohlfing et al.,](#page-13-4) [2010\)](#page-13-4), and resampling to an isotropic resolution of 1 mm3. The pre-processing pipeline is publicly available through the Cancer Imaging Phenomics Toolkit (CaPTk) [\(Pati et al.,](#page-13-5) [2020;](#page-13-5) [Rathore et al., 2018;](#page-13-6) [Davatzikos et al., 2018\)](#page-12-23) and Federated Tumor Segmentation (FeTS) tool [\(Pati et al.,](#page-13-7) [2022\)](#page-13-7) (https://github.com/FETS-AI/Front-End/). The deidentification was performed through removing protected health information from DICOM headers. De-facing was performed via skull-stripping using a pediatric-specific skullstripping method [\(Fathi Kazerooni et al., 2023a\)](#page-12-3) to prevent any potential facial reconstruction/recognition of the patients. Figure 1A presents the data preparation workflow.

The pre-processed images were segmented into tumor subregions using either of two pediatric automated deep learning segmentation models [\(Fathi Kazerooni et al., 2023a;](#page-12-3) [Liu et al., 2023\)](#page-12-10) before being manually corrected by pedi-the pediatric data, to follow the guidelines of the other

atric neuro-radiologists. The tumors were segmented into four subregions. These subregions comprising of enhancing tumor (ET), non-enhancing tumor (NET), cystic component (CC), and peritumoral edema (ED) regions, with definitions provided in [\(Familiar et al., 2024\)](#page-12-2), and summarized below:

- ET is described by areas with enhancement (brightness) on T1 post-contrast images as compared to T1 pre-contrast. In case of mild enhancement, checking the signal intensity of normal brain structures can be helpful.
- CC typically appears with hyperintense signal (very bright) on T2 and hypointense signal (dark) on T1CE. The cystic portion should be within the tumor, either centrally or peripherally (as compared to ED which is peritumoral). The brightness of CC is defined as comparable or close to cerebrospinal fluid (CSF).
- NET is defined as any other abnormal signal intensity within the tumorous region that cannot be defined as enhancing or cystic. For example, the abnormal signal intensity on T1, T2-FLAIR, and T2 that is not enhancing on T1CE should be considered as nonenhancing portion.
- ED is defined by the abnormal hyperintense signal (very bright) on FLAIR scans. ED is finger-like spreading that preserves underlying brain structure and surrounds the tumor.

The American Society of Neuroradiology (www.asnr.org, ASNR) collaborated in generating ground truth annotation for the majority of data in this challenge. Four labels were generated (Figure 1) using the preliminary automated segmentation and were then manually revised by ASNR volunteer neuroradiology experts of varying rank and experience in accordance with the annotation guidelines. The expert annotators were provided with the four mpMRI sequences (T1, T1CE, T2, FLAIR) along with the fused automated segmentation volume to initiate the manual refinements using the ITK-SNAP software [\(Yushkevich et al.,](#page-13-8) [2006\)](#page-13-8). After segmentation corrections by the annotators, three attending board-certified neuroradiologists reviewed the segmentations to either approve or return to the individual annotators for further refinements. This process was followed iteratively until the approvers found the refined tumor subregion segmentations acceptable for public release and the challenge conduction. The final segmentations were provided and used as ground truth for model training and evaluation.

Although four tumor subregions were annotated for all

Figure 1: A schematic diagram of different steps in data preparation for BraTS-PEDs 2023 data: (A) Data preparation process; (B) Tumor segmentation approach: Left - original annotations including four subregions, Right – final annotations provided to the teams for model training (the final annotations and their label values were prepared in agreement with other BraTS 2023 challenges). The color maps in the images shown in Figure 1B illustrate the label descriptions provided in the original annotations given to the annotators (left), as compared to the final annotations (right) – which adhere to the standards of other BraTS challenges – provided to the teams; (C) Evaluation labels: for calculating the performance metrics, ET, TC (combination of ET and NC), and WT (a combination of ET, NC, ED) were used.

BraTS 2023 challenges and to allow the teams to potentially incorporate data from adult glioma challenge into their model training, the teams were provided with only three segmentation labels, i.e., non-enhancing component (NC – the union of non-enhancing tumor, cystic component, and necrosis; label 1), ED (label 2), and ET (label 3), as shown in Figure 1B. The color maps in the images shown in Figure 1B illustrate the label descriptions provided in the original annotations given to the annotators (Figure 1B; left), as compared to the final annotations (Figure 1B; right) – which adhere to the standards of other BraTS challenges – provided to the teams.

2.3 Challenge Setup

The BraTS-PEDs 2023 cohort was split into training $(n =$ 98), validation ($n = 44$), and testing datasets ($n = 24$). Training and validation included a random split between CBTN and Boston cases. All Yale cases were used for independent testing. The training data shared with the teams comprised mpMRI scans and ground truth labels for the training cohort, released in mid-May 2023. The cohort shared for validation included only the mpMRI sequences without associated ground truth and it was released in late June 2023. Notably, the testing cohort was kept "unseen" to participants.

Teams were prohibited from training their algorithm on any additional public and/or private data besides the provided BraTS-PEDs 2023 data or to using models pretrained on other datasets. This restriction was imposed to allow for a direct and fair comparison among the participating methods. However, teams were allowed to use additional public and/or private data for publication of their scientific papers, on the condition that they also provide a report of their results on the data from BraTS-PEDs 2023 challenge alone and discuss potential differences in the obtained results.

The methods submitted to the BraTS-PEDs 2023 challenge were evaluated based on performances for the segmentation of ET, tumor core (TC – the combination of ET and NC), and the entire tumorous region, or whole tumor (WT – the union of ET, NC, and ED) (Figure 1C). The containerized submissions of the teams were evaluated on the synapse.org platform supported by Medperf [\(Karargyris](#page-12-24) [et al., 2023\)](#page-12-24). Teams were required to send the output of their methods to the evaluation platform for the scoring to occur during the training and the validation phases. At the end of the validation phase, teams were asked to identify the method they would like to be evaluated by the organizers in the final testing/ranking phase. The training, validation, and testing phases ran between May-July 2023, July-August 2023, and August 2023, respectively. The results and ranking of the challenge were presented at the MICCAI 2023 conference on October 10, 2023.

2.4 Benchmark Design: Evaluation and Ranking

The evaluation and ranking were based on a lesionwise ranking scheme in which the ranking for each team was computed relative to other challenge competitors for each of the subjects in the test set, for each tumor region, e.g., ET, TC, and WT. We used two established performance evaluation metrics, i.e., Dice similarity coefficient (Dice) and 95% Hausdorff distance (HD95) using the Generally Nuanced Deep Learning Framework (GaNDLF; gandlf.org) [\(Pati et al., 2023\)](#page-13-9). At BraTS-PEDs 2023, each team was ranked for 24 test subjects, 3 tumor regions, and 2 metrics, resulting in 144 individual rankings. Then for each team, the final ranking score (FRS) was computed by producing a cumulative rank as an average of all individual rankings for each patient, followed by averaging the cumulative ranks across all testing subjects for each competing team.

The lesion-wise Dice and HD95 were calculated by isolating and identifying each disjoint lesion, through dilating the ground truth segmentation masks for each tumor region, i.e., ET, TC, and WT, by 3 pixels in all directions (i.e., by a size of $3x3x3$). Dice and HD95 scores were calculated for each component or lesion individually, after penalizing all false positive and false negative values with a score of 0. Subsequently, the mean value of Dice and HD95 scores across all lesions were calculated for each subject.

The lesions below a cutoff value of 50 voxels were removed from any further evaluation. If the models were not able to predict a region for a subject, the Dice score was assigned a value of 0 and HD95 was set to 374 (the distance between corners in the SRI atlas space), and if they correctly did not predict a non-existing region, the Dice score and HD95 were given values of 1 and 0, respectively. Lesionwise Dice and HD95 scores for each case were calculated according to equations 1 and 2. More information on the evaluation metrics along with the codes can be found at https://github.com/rachitsaluja/BraTS-2023-Metrics.

$$
LesionwiseDiceScore = \frac{\Sigma_i^LDice(l_i)}{TP + FN + FP}
$$
 (1)

$$
LesionwiseHD95 = \frac{\Sigma_i^L HD95(l_i)}{TP + FN + FP}
$$
 (2)

Where L represents the number of ground truth lesions, TP denotes the number of true positives, FN indicates the number of false negatives, and FP signifies the number of false positives.

Finally, the statistical differences in performance, beyond those expected by chance, between each pair of teams were determined using permutation testing. This was achieved for each pair of teams, by randomly permuting the cumulative ranks for each subject and calculating the difference in FRS between the pair of teams in each permutation. Statistical significance of rankings was determined using a p-value when the proportion of times the difference in FRS using the permutated data exceeded the observed difference in FRS using the actual data. These values are reported in an upper triangular matrix.

2.5 Data Availability

The training data, including ground truth segmentations, and the validation data without ground truth segmentations can be accessed and downloaded from the Synapse www.synapse.org/Synapse:syn51156910/wiki/627000. More information about the BraTS-PEDs 2023 challenge is at www.synapse.org/Synapse:syn51156910/wiki/622461.

3. Results

Of the participating teams in the training phase of the challenge, 18 teams with 159 submissions participated in the validation phase, with 147 submissions being scored. Nine of these teams completed all stages of the challenge and were evaluated during the testing phase of the BraTS-PEDs 2023 challenge. Table 1 provides a summary of the cumulative ranks and FRS for each team across all test subjects, including the teams' rankings, and a high-level description of the methods used by each team. The CN-MCPMI2023 team achieved the highest score among the

Teams	Method	Cumulative Ranks Across Subjects	FRS	Rank in the Challenge
CNMCPMI2023	Ensemble of nnU-Net and Swin UNETR	241.5	10.06	$-$ a
NVAUTO	Auto3DSeg	246	10.25	
SherlockZyb	nnU-Net (self-supervised)	286.5	11.93	
Blackbean	Scalable and Transferable U-Net (STU-Net)	290.5	12.1	
BiomedMBZ	Ensemble of SegResnet and MedNext	318	13.25	
SchlaugLab	Ensemble of ONet and UNet	395.5	16.47	
VisionLabODU23	Multiresolution Fractal Deep Neural Network (MFDNN)	427	17.79	
Isahajmistry	Modified nnU-Net	483	20.12	
UMNiverse	Temporal Cubic PatchGAN (TCuP-GAN)	552	23	

Table 1: Cumulative ranks across testing subjects and final ranking score (FRS) for the competing teams in the BraTS-PEDs2023 challenge. The lower ranks show better performance.

a. Participating teams that included challenge organizers underwent evaluation without ranking to uphold fairness in our benchmarking initiative. This approach aligns with MICCAI guidelines, as well as the CBTN policy for hackathons.

Table 2: Summary of the performance evaluation metrics for segmentation of enhancing tumor (ET) region for the participating teams. The results are shown in mean \pm standard deviation (median) format.

Teams	Dice Similarity Coefficient	95% Hausdorff Distance	Sensitivity
CNMCPMI2023	0.65 ± 0.32 (0.74)	43.89 ± 108.59 (3.67)	0.70 ± 0.18 (0.74)
NVAUTO	0.55 ± 0.37 (0.68)	115.32 ± 144.03 (4.04)	0.77 ± 0.20 (0.80)
SherlockZyb	0.63 ± 0.32 (0.71)	59.68 ± 116.70 (3.93)	0.71 ± 0.27 (0.74)
Blackbean	0.53 ± 0.34 (0.60)	22.02 ± 52.12 (5.83)	0.63 ± 0.31 (0.71)
BiomedMBZ	0.55 ± 0.27 (0.61)	45.32 ± 109.10 (5.69)	0.80 ± 0.29 (0.92)
SchlaugLab	0.55 ± 0.36 (0.65)	65.23 ± 122.23 (4.30)	0.55 ± 0.37 (0.59)
VisionLabODU23	0.17 ± 0.38 (0)	311.67 ± 142.38 (374)	0.17 ± 0.38 (0)
Isahajmistry	0.48 ± 0.36 (0.49)	$128.12 \pm 147.11 \ (10.85)$	0.66 ± 0.35 (0.82)
UMNiverse	0.17 ± 0.38 (0)	311.67 ± 142.38 (374)	0.17 ± 0.38 (0)

Table 3: Summary of the performance evaluation metrics for segmentation of tumor core (TC) region for the participating teams. The results are shown in mean \pm standard deviation (median) format.

teams, followed by NVAUTO, SherlockZyb, and Blackbean (see Table 1 that illustrates the scores and methods used by all teams that completed the challenge tasks).

Figure 2 illustrates the p-values calculated between pairs of teams to evaluate statistical significance between the achieved performance. Specifically, among the best performing teams, the results for CNMCPMI2023 and NVAUTO sensitivity—of each team. The CNMCPMI2023 | NVAUTO $({\mathsf p}~=~0.45)$, NVAUTO and SherlockZyb $({\mathsf p}~=~0.1)$, and $~\mid$ SherlockZyb \mid Blackbean teams achieved Dice scores of

SherlockZyb and Blackbean ($p = 0.43$) were not significantly different. This may be due to the small sample size of the test cohort ($n = 24$) for this challenge.

Figures 3 to 5 display the Dice and HD95 scores for all test subjects for all the participating teams. Tables 2 to 4 summarize the performance metrics—Dice, HD95, and

Teams	Dice Similarity Coefficient	95% Hausdorff Distance	Sensitivity
CNMCPMI2023	0.83 ± 0.18 (0.87)	20.86 ± 75.31 (4.24)	0.76 ± 0.18 (0.81)
NVAUTO	0.84 ± 0.16 (0.87)	18.05 ± 62.77 (4.30)	0.80 ± 0.09 (0.82)
SherlockZyb	0.83 ± 0.17 (0.87)	6.11 ± 4.50 (4.79)	0.75 ± 0.17 (0.80)
Blackbean	0.81 ± 0.15 (0.86)	23.56 ± 61.60 (4.95)	0.78 ± 0.07 (0.80)
BiomedMBZ	0.78 ± 0.20 (0.82)	30.45 ± 82.46 (6.85)	0.72 ± 0.19 (0.77)
SchlaugLab	0.79 ± 0.18 (0.84)	22.36 ± 75.20 (5.92)	0.71 ± 0.18 (0.75)
VisionLabODU23	0.68 ± 0.26 (0.81)	68.18 ± 69.56 (6.35)	0.73 ± 0.21 (0.79)
Isahajmistry	0.35 ± 0.23 (0.29)	221.95 ± 99.53 (250.67)	0.76 ± 0.20 (0.81)
UMNiverse	0.60 ± 0.25 (0.70)	$72.62 \pm 107.48(10.69)$	0.61 ± 0.16 (0.59)

Table 4: Summary of the performance evaluation metrics for segmentation of whole tumor (WT) region for the participating teams. The results are shown in mean \pm standard deviation (median) format.

Figure 2: Pairwise p-values between the participating teams.

0.83 | 0.84 | 0.83 | 0.81 for WT, 0.81 | 0.78 | 0.77 | 0.79 for TC, and 0.65 | 0.55 | 0.63 | 0.53 for ET segmentation, and HD95 values of 20.86 | 18.05 | 6.11 | 23.56 for WT, 21.82 | 27.10 | 22.28 | 22.02 for TC, and 43.89 | 115.32 | 59.68 | 22.02 for ET segmentation. Interestingly, the sensitivity of the NVAUTO algorithm for the segmentation of WT and ET was higher than that of the other two teams, indicating a higher overall rate of true positive predictions by this algorithm. However, this increased sensitivity came at the cost of over-segmentation, resulting in more false positives and less accurate boundary placement for ET segmentation.

The prediction results for ET demonstrate a greater variability and skewness in the Dice score distribution, as indicated by the mean and median values in Table 2 and the box plots in Figure 3. In contrast, the segmentation of TC

Figure 3: Dice and HD95 Scores for segmentation of enhancing tumor (ET) across participating teams in the BraTS-PEDs 2023 Challenge.

Figure 4: Dice and HD95 Scores for segmentation of tumor core (TC) across participating teams in the BraTS-PEDs 2023 Challenge.

Figure 5: Dice and HD95 Scores for segmentation of whole tumor (WT) across participating teams in the BraTS-PEDs 2023 Challenge.

and WT (Figures 4-5) shows less variability and skewness. Given the small volume or absence of the ET region in DMG tumors, the Dice score more heavily penalizes segmentation errors in the ET region. TC and WT segmentations are more consistent and accurate across all teams, with WT segmentation being the most precise. This indicates that, on average, most methods reliably locate the lesion within MRI scans, while distinguishing between different tumor compartments is more challenging.

Figure 6 showcases examples of the performances of CNMCPMI2023, NVAUTO, SherlockZyb, and Blackbean teams for tumor segmentation in four testing subjects. Panels (A-B) indicate the best results for these three teams, with WT Dice above 0.90. Panels (C-D) present the subjects with worst results across the top performing teams. As indicated in these examples, there are situations where one algorithm performs better than the remaining algorithms in segmentation of tumorous regions. In Figure Dice scores of 0.88, while NVAUTO achieved a low Dice score (0.18) for WT segmentation. This low performance for NVAUTO was achieved due to many false positive results for segmentation of the tumor for this subject. On the other hand, in the example presented in Figure 6(D), NVAUTO and Blackbean algorithms produced WT segmentation results with Dice scores of 0.60 and 0.70, respectively, while the other two algorithms, i.e., CNMCPMI2023 and SherlockZyb, did not generate any segmentation outputs (WT Dice $= 0$ or 0.05). This situation underscores the potential benefit of ensembling different algorithms in achieving better overall performance.

4. Discussion

The results of the BraTS-PEDs 2023 challenge provide valuable insights into different automated volumetric segmentation methods for pediatric brain tumors. The comprehensive evaluation metrics and rigorous validation phase in this challenge highlight the strengths and weaknesses of the various methods, offering a clear benchmark for future developments.

4.1 Overview of the Challenge Results

6(C), CNMCPMI2023, SherlockZyb, and Blackbean achieved methods—developed for adult glioma segmentation—on a In 2022, the BraTS Glioma challenge tested the top-performing small set of unseen pediatric brain tumor data. Results revealed that although models trained on adult brain tumors achieved high Dice scores for segmenting the whole pediatric tumor from mpMRI scans, their performance on tumor subregions (such as ET or NC) was inaccurate. This confirmed our hypothesis that effective pediatric segmentation techniques require training on a curated and an-

Figure 6: Examples of tumor segmentation for sample testing patients across the best performing teams: (A-B) best cases; (C-D) worst cases.

notated pediatric brain tumor dataset. However, as with any machine learning and deep learning endeavor, developing a model that generalizes well necessitates a large, standardized dataset. To address this, the BraTS-PEDs 2023 initiative has compiled the most extensive annotated collection of pediatric high-grade gliomas, including astrocytomas and DMGs.

The top-performing methods at BraTS-PEDs 2023 included an ensemble method combining nnU-Net and Swin UNETR, Auto3DSeg using the SegResNet algorithm, and an extension of the nnU-Net model with self-supervised pretraining integrated with adaptive region-specific loss. All of these methods are based on the U-Net convolutional neural network architecture. The models achieved mean Dice scores of 0.83-0.84 for WT segmentation and slightly lower yet respectable Dice scores of 0.77-0.81 for TC segmentation. However, lower and more variable performance was observed in the segmentation of the ET region, with mean Dice scores of 0.65, 0.63 and 0.55 across the three top performing teams, which emphasizes the unique challenges posed by pediatric brain tumors. The small volume or absence of ET region in DMG likely contributes to the greater variability and skewness in the Dice score distribution for this subregion. This finding indicates that while most methods can reliably locate the WT within MRI scans, accurately distinguishing between different tumor compartments remains a significant challenge in pediatric brain tumors.

The examples in the manuscript demonstrate that no single algorithm consistently outperforms others across all cases. The variability in performance, especially in challenging scenarios, highlights the need for continued research and development in this field. Specifically, ensembling the top-performing models may achieve better overall performance for segmentation of multi-institutional data by leveraging their individual strengths and mitigating their weaknesses. For instance, a method with high sensitivity, despite relatively lower Dice and higher HD95 scores, can be useful when it is critical not to miss any positive regions (such as in ET segmentation). By combining this method with others, it can be refined to reduce false positives and improve boundary accuracy.

4.2 Limitations

There were several limitations at BraTS-PEDs 2023, including the small size of the dataset and the limited types of pediatric brain tumor histologies. The statistical analysis of performance between the top teams revealed no significant differences, which may be attributed to the small sample size of the test cohort ($n = 24$). This limitation suggests that future challenges could benefit from larger test cohorts to better discern performance differences and validate the robustness of the algorithms. In addition, to align with the rest of the BraTS 2023 cluster of challenges, we focused our evaluation on the segmentation of enhancing tumor, tumor core, and whole tumor, which may limit application of these methods for response assessment in pediatric brain tumors. Recognizing the distinct differences between adult and pediatric brain tumors [\(Familiar et al.,](#page-12-2) [2024\)](#page-12-2), especially in components critical for response assessment [\(Familiar et al., 2024;](#page-12-2) [Cooney et al., 2020;](#page-12-5) [Erker](#page-12-4) [et al., 2020\)](#page-12-4), we will customize future evaluations to better address pediatric tumor characteristics. Furthermore, the typically small size of ET regions in DMG tumors prompted us to set a threshold of 50 voxels for the detection of a true positive, which might have impacted the accuracy of ET predictions. Moving forward, we intend to adopt a more data-driven approach to setting this threshold in subsequent challenges.

4.3 Future Directions

Encouraged by the results of the BraTS-PEDs 2023 challenge, our next steps include expanding the dataset to include subjects from additional institutions and incorporating various histologies of high- and low-grade pediatric glioma. This initiative will offer the research community access to a comprehensive dataset of rare pediatric tumors with curated mpMRI and annotation, thereby aiding in the development of advanced tools for computer-assisted treatment planning and prognosis. Future data collection will also encompass post-operative and post-treatment scans and clinical outcomes. The data is publicly available at www.synapse.org/Synapse:syn51156910/wiki/627000.

5. Conclusion

The BraTS-PEDs 2023 challenge provided an open-access, curated, annotated dataset of multi-sequence MRIs of pediatric brain tumors. The challenge also provided the platform to evaluate methods for automated volumetric segmentation of pediatric brain tumors, thereby supporting the development of techniques that enhance decision support systems for assessing treatment responses and predicting the outcomes of these rare conditions. This manuscript presented the overview and results of the BraTS-PEDs 2023 challenge.

Acknowledgments

Success in any challenging medical domain depends upon the quality of well annotated multi-institutional datasets. We are grateful to all the data contributors, annotators, and approvers for their time and efforts. Our profound thanks go to the Children's Brain Tumor Network (CBTN), the Collaborative Network for Neuro-oncology Clinical Trials (CONNECT), the International DIPG/DMG Registry (IDIPGR), the American Society of Neuroradiology (ASNR), and the Medical Image Computing and Computer Assisted Intervention (MICCAI) Society for their invaluable support of this challenge.

Research reported in this publication was partly supported by the National Institutes of Health (NIH) award: NCI/ITCR:U01CA242871 and NCI:UH3CA236536, and by grant funding from the Pediatric Brain Tumor Foundation and DIPG/DMG Research Funding Alliance (DDRFA). The content of this publication is solely the responsibility of the authors and does not represent the official views of the NIH.

Ethical Standards

For this retrospective study, informed consent had been obtained from all subjects at their respective institutions or a waiver of informed consent was approved by the local institutional review board. The protocol for releasing the data was approved by the institutional review board of the data-contributing institution. All patients were fully de-identified and stripped of any patient identifiers before sharing with the organizing team. Further de-identification was performed through renaming all images and the respective ground truth segmentations, and defacing all MRI images through skull-stripping before sharing with the participants.

Conflicts of Interest

None of the authors have any conflicts of interest related to this manuscript.

Data availability

The training data, including ground truth segmentations, and the validation data without ground truth segmentations can be accessed and downloaded from the Synapse www.synapse.org/Synapse:syn51156910/wiki/627000. More information about the BraTS-PEDs 2023 challenge is at www.synapse.org/Synapse:syn51156910/wiki/622461.

References

- M. Artzi et al. Automatic segmentation, classification, and follow-up of optic pathway gliomas using deep learning and fuzzy c-means clustering based on mri. Medical Physics, 47(11):5693–5701, 2020.
- U. Baid et al. The rsna-asnr-miccai brats 2021 benchmark on brain tumor segmentation and radiogenomic classification. arXiv:2107.02314, 2021.
- S. Bakas et al. Advancing the cancer genome atlas glioma mri collections with expert segmentation labels and radiomic features. Scientific data, 4(1):1–13, 2017.
- S. Bakas et al. Identifying the best machine learning algorithms for brain tumor segmentation, progression assessment, and overall survival prediction in the brats challenge. arXiv:1811.02629, 2018.
- T.M. Cooney et al. Response assessment in diffuse intrinsic pontine glioma: recommendations from the response assessment in pediatric neuro-oncology (rapno) working group. The Lancet Oncology, 21(6):e330–e336, 2020.
- C. Davatzikos et al. Cancer imaging phenomics toolkit: quantitative imaging analytics for precision diagnostics and predictive modeling of clinical outcome. Journal of medical imaging, 5(1):011018–011018, 2018.
- B.M. Elingson et al. Volumetric measurements are preferred in the evaluation of mutant idh inhibition in nonenhancing diffuse gliomas: evidence from a phase i trial of ivosidenib. Neuro-Oncology, 24(5):770–778, 2022.
- C. Erker et al. Response assessment in paediatric highgrade glioma: recommendations from the response assessment in pediatric neuro-oncology (rapno) working group. The Lancet Oncology, 21(6):e317–e329, 2020.
- A.M. Familiar et al. Towards consistency in pediatric brain tumor measurements: Challenges, solutions, and the role of ai-based segmentation. Neuro-Oncology, page noae093, 2024.
- A. Fathi Kazerooni et al. Automated tumor segmentation and brain tissue extraction from multiparametric mri of pediatric brain tumors: A multi-institutional study. Neuro-Oncology Advances, 5(1):vdad027, 2023a.
- M.H. Jansen et al. Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro-Oncology, 17(1):160– 166, 2015.
- A. Karargyris et al. Federated benchmarking of medical artificial intelligence with medperf. Nat Mach Intell, 5: 799–810, 2023.
- A.F. Kazerooni et al. The brain tumor segmentation (brats) challenge 2023: Focus on pediatrics (cbtn-connectdipgr-asnr-miccai brats-peds). arXiv, 2023b.
- M. Kharaji et al. Brain tumor segmentation with advanced nnu-net: Pediatrics and adults tumors. Neuroscience Informatics, page 100156, 2024.
- F. Kofler et al. The brain tumor segmentation (brats) challenge 2023: Local synthesis of healthy brain tissue via inpainting. arXiv:2305.08992, 2023.
- D. LaBella et al. The asnr-miccai brain tumor segmentation (brats) challenge 2023: Intracranial meningioma. arXiv:2305.07642, 2023.
- M.A. Lazow et al. Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the international dipg/dmg registry. Neuro-Oncology, 24(9):1598–1608, 2022.
- H.B. Li et al. The brain tumor segmentation (brats) challenge 2023: Brain mr image synthesis for tumor segmentation (brasyn). arXiv, 2023.
- J.V. Lilly et al. The children's brain tumor network (cbtn) accelerating research in pediatric central nervous system tumors through collaboration and open science. Neoplasia, 35:100846, 2023.
- X. Liu et al. From adult to pediatric: deep learning-based automatic segmentation of rare pediatric brain tumors. In Proceedings of SPIE Medical Imaging: Computer-Aided Diagnosis, volume 12465, page 1246505, 2023.
- A. Mackay et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer cell, 32(4):520–537, 2017.
- A. Mansoor et al. Deep learning guided partitioned shape model for anterior visual pathway segmentation. IEEE transactions on medical imaging, 35(8):1856– 1865, 2016.
- B.H. Menze et al. The multimodal brain tumor image segmentation benchmark (brats). IEEE transactions on medical imaging, 34(10):1993–2024, 2014.
- A.W. Moawad et al. The brain tumor segmentation (bratsmets) challenge 2023: Brain metastasis segmentation on pre-treatment mri. arXiv, 2023.
- J. Nalepa et al. Segmenting pediatric optic pathway gliomas from mri using deep learning. Computers in Biology and Medicine, 142:105237, 2022.
- S. Pati et al. The cancer imaging phenomics toolkit (captk): technical overview. In Proceedings of MIC-CAI Brainlesion: Glioma, Multiple Sclerosis, Stroke and Traumatic Brain Injuries Workshop, 2020.
- S. Pati et al. Federated learning enables big data for rare cancer boundary detection. Nature communications, 13 (1):7346, 2022.
- S. Pati et al. Gandlf: the generally nuanced deep learning framework for scalable end-to-end clinical workflows. Communications Engineering, 2:23, 2023.
- J. Peng et al. Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors. Neuro-Oncology, 24(2):289–299, 2022.
- S. Rathore et al. Brain cancer imaging phenomics toolkit (brain-captk): an interactive platform for quantitative analysis of glioblastoma. In Proceedings of MICCAI Brainlesion: Glioma, Multiple Sclerosis, Stroke and Traumatic Brain Injuries Workshop, 2018.
- T. Rohlfing et al. The sri24 multichannel atlas of normal adult human brain structure. Human brain mapping, 31 (5):798–819, 2010.
- J.P. Thakkar et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev, 23(10):1985–1996, 2014.
- C. Tor-Diez et al. Unsupervised mri homogenization: application to pediatric anterior visual pathway segmentation. In Proceedings of MICCAI Machine Learning in Medical Imaging (MLMI) Workshop, volume 12436, pages 180– 188, 2020.
- A. Vossough et al. Training and comparison of nnu-net and deepmedic methods for autosegmentation of pediatric brain tumors. American Journal of Neuroradiology, 2022.
- P.A. Yushkevich et al. User-guided 3d active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage, 31(3): 1116–1128, 2006.